Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ITERUM THERAPEUTICS PLC

(ITRM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Iterum Therapeutics : FDA Recommends More Data on Oral Sulopenem

07/26/2021 | 05:53am EDT

By Chris Wack

Iterum Therapeutics PLC said the U.S. Food and Drug Administration decided it can't approve the company's new drug application for sulopenem etzadroxil/probenecid oral sulopenem in its present form.

The FDA acknowledged in a letter Friday that the Phase 3 clinical trial demonstrated statistical significance in difference in overall response rate of oral sulopenem compared to ciprofloxacin in the ciprofloxacin-resistant population, Iterum said.

However, the FDA determined that additional data are necessary to support approval for the treatment of adult women with uncomplicated urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be non-susceptible to a quinolone, the company said.

The FDA recommended that Iterum conduct at least one additional adequate and well-controlled clinical trial, potentially using a different comparator drug, the company said.

Additionally, the FDA recommended that Iterum conduct further nonclinical investigation to determine the optimal dosing regimen, although the FDA stated that this recommendation doesn't raise an approvability issue, the company said.

The FDA didn't identify any chemistry, manufacturing or controls issues, nor were there any safety issues found in over 1,800 patients treated with sulopenem across the clinical development program, the company said.

Iterum intends to review the FDA's decision with its advisers and plans to request a Type A meeting in the coming weeks. Following the meeting, anticipated to be late in the third quarter, Iterum expects to provide an update on next steps as to the potential additional clinical and non-clinical work to be done prior to a resubmission of the NDA for approval of oral sulopenem.

Iterum said it had cash, cash equivalents and short-term investments of $100.5 million at the end of the first quarter of 2021. Based on the current operating plan and subject to final determination of the design and planned conduct of additional clinical and potential nonclinical development for sulopenem, the company believes that it is well positioned financially to fund its operations into the second half of 2023.

The company had said in May that it was aiming to launch oral sulopenem in the fourth quarter of 2021, if approved.

Iterum shares were down 39% to 69 cents.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

07-26-21 0753ET

All news about ITERUM THERAPEUTICS PLC
09/15ITERUM THERAPEUTICS : ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Iterum Ther..
PR
09/10ITERUM THERAPEUTICS : Delisting/Transfer of Listing (Form 8-K)
PU
09/10ITERUM THERAPEUTICS PLC : Notice of Delisting or Failure to Satisfy a Continued ..
AQ
09/09ITERUM THERAPEUTICS (NASDAQ : ITRM) INVESTOR FILING DEADLINE: Bernstein Liebhard..
PR
09/08ITERUM THERAPEUTICS : to Present at the H.C. Wainwright 23rd Annual Global Inves..
AQ
09/05SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
08/28ITERUM THERAPEUTICS : ROSEN, A TRUSTED AND TOP RANKED LAW FIRM, Encourages Iteru..
PR
08/27ITERUM THERAPEUTICS : Pomerantz Law Firm Announces the Filing of a Class Action ..
PR
08/19ITERUM THERAPEUTICS : Pomerantz Law Firm Announces the Filing of a Class Action ..
PR
08/17ITERUM THERAPEUTICS : ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Iterum Therapeu..
BU
More news
Analyst Recommendations on ITERUM THERAPEUTICS PLC
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -77,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,16x
Yield 2021 -
Capitalization 110 M 110 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 7
Free-Float 99,4%
Chart ITERUM THERAPEUTICS PLC
Duration : Period :
Iterum Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ITERUM THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 0,60 $
Average target price 1,00 $
Spread / Average Target 65,6%
EPS Revisions
Managers and Directors
Corey N. Fishman President, Chief Executive Officer & Director
Judith M. Matthews Chief Financial Officer
Brent K. Ahrens Chairman
Tom Loughman Senior Vice President-Technical Operations
Ronald M. Hunt Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ITERUM THERAPEUTICS PLC-38.96%110
MODERNA, INC.315.87%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.44.30%49 541
CELLTRION, INC.-25.63%31 848
SEAGEN INC.-13.16%27 670